HANGZHOU, China, July 8, 2026 /PRNewswire/ -- Altruist Biologics, an Innovent Biologics subsidiary and world-class contract development and manufacturing organization (CDMO), announced that its application for segmented production of antibody-drug conjugates (ADCs) at its Hangzhou site successfully passed a comprehensive inspection from three provincial regulatory bodies in China. This is the first case to receive a trilateral approval and marks a further upgrade of the company's ADC manufacturing expertise and integrated capabilities.
Dr. Kaisong Zhou, Chairman and CEO of Altruist Biologics, said, "Quality is the foundation of everything we do at Altruist. Our integrated global quality system enables us to consistently deliver the highest standards of compliance, reliability, and operational excellence while supporting the evolving needs of our partners worldwide. As we continue to expand our global capabilities, we remain committed to accelerating the development and manufacture of innovative therapies that help bring life-changing medicines to patients around the world."
Altruist Biologics' Hangzhou site offers a standalone ADC & AXC bioconjugation facility, which supports the manufacture of various bioconjugates including high potency ADCs for clinical and commercial supply in both small- and large-scale production. It includes fully integrated laboratories dedicated to ADC process development, quality control, and MSAT to support seamless progression from development through manufacturing.
The facility features single-use reactor systems supporting conjugation scales of up to 500 L with 1,000 L-5,000 L under construction, ultimately providing the flexibility and capacity required for scalable ADC drug substance manufacturing. It also has fully automated, isolator-based aseptic filling system with two 7.5m2 and three 35m2 lyophilizers.
It is designed for the safe handling of high-potency APIs (HPAPIs) and incorporates stringent high-containment systems with an Occupational Exposure Limit (OEL) capability of 5 ng/m³, ensuring the highest standards of safety, regulatory compliance, and operational control.
The company has successfully managed over 40 ADC and AXC projects, and has developed ADC molecules spanning from pre-IND to phase three and PPQ. For more information about Altruist Biologics' ADC and bioconjugate capabilities, please visit: www.altruistbio.com.
About Altruist Biologics
Altruist Biologics is a reliable CDMO service provider and wholly owned subsidiary of Innovent Biologics, focusing on the development, clinical, and commercial manufacturing of antibodies, fusion proteins, recombinant proteins, antibody drug conjugates, and other drugs. The company operates advanced cGMP facilities in Suzhou and Hangzhou, China, with a total production capacity of 232,000 liters, and continues to invest in new capabilities to maximize operational and quality excellence, ensuring flexibility, safety, and agility for clients. With over a decade of bioprocessing expertise, the company has supported the commercialization of 18 drugs and completed more than 2,000 commercial batches with a >99.8% success rate. Its track record includes 100 global regulatory filings with the FDA, EMA, NMPA, PMDA, TGA, and BPOM as well as over 80 successful authority audits. With over 1,000 employees, including leading experts and scientists spanning all areas of biologics production and innovation, Altruist is committed to supporting clients in developing affordable and high-quality biopharmaceuticals for the benefit of patients worldwide.
Media Contact:
Courtney Garcia
Director of Global Marketing & Communications
courtney.garcia@altruistbio.com
Logo - https://mma.prnewswire.com/media/3004350/Altruist_Logo_Color_Logo.jpg
View original content:https://www.prnewswire.co.uk/news-releases/altruist-biologics-hangzhou-antibody-drug-conjugate-facility-receives-provincial-regulatory-approval-for-segmented-production-302818609.html
Die Mayr-Melnhof Gruppe (MM Gruppe) zählt erstmals zu den „Europe’s Climate Leaders 2026“, einem Ranking der Financial Times, das europäische Unternehmen mit nachweislichen Fortschritten beim Klimaschutz auszeichnet. Die Aufnahme in die Liste gilt für den Konzern als zusätzliche externe Bestätigung seiner langfristig ausgerichteten Nachhaltigkeitsstrategie und der bisherigen Reduktion von Treibhausgasemissionen.
Das Ranking wurde von Statista in Zusammenarbeit mit der Financial Times erstellt und umfasst insgesamt 600 Unternehmen aus Europa. Bewertet wurden vor allem die Verringerung der direkten und indirekten kernnahen Emissionen (Scope 1 und Scope 2) sowie die Entwicklung der Emissionsintensität im Zeitraum von 2019 bis 2024. Ergänzend flossen klimabezogene Kennzahlen wie Bewertungen durch die Non-Profit-Organisation CDP und die Zielsetzungen im Rahmen der Science Based Targets initiative (SBTi) in die Analyse ein.
Für die MM Gruppe zahlt sich insbesondere ihre ESG-Positionierung aus: Das Unternehmen verweist auf eine CDP-„Triple-A“-Bewertung in den Bereichen Klimawandel, Wälder und Wassersicherheit. Zudem sind die Klimaziele des Karton- und Verpackungsspezialisten von der SBTi validiert und an einem Dekarbonisierungspfad ausgerichtet, der sich am 1,5-Grad-Ziel orientiert. Diese Faktoren waren mitentscheidend für die Einstufung als eines der führenden europäischen Unternehmen beim Klimaschutz.
Vorstandsvorsitzender Peter Oswald sieht in der Auszeichnung den Beleg für die konsequente Umsetzung der Nachhaltigkeitsagenda der vergangenen Jahre. Die Kombination aus ambitionierten, wissenschaftsbasierten Zielen und der Übersetzung dieser Ziele in messbare Emissionsreduktionen stärke aus seiner Sicht nicht nur die ökologische Bilanz, sondern auch die unternehmerische Positionierung der MM Gruppe im europäischen Markt.
